JP2005518379A - プロテインキナーゼ阻害剤としてのｎ−炭素環式単置換インドロカルバゾール - Google Patents

プロテインキナーゼ阻害剤としてのｎ−炭素環式単置換インドロカルバゾール Download PDF

Info

Publication number
JP2005518379A
JP2005518379A JP2003552769A JP2003552769A JP2005518379A JP 2005518379 A JP2005518379 A JP 2005518379A JP 2003552769 A JP2003552769 A JP 2003552769A JP 2003552769 A JP2003552769 A JP 2003552769A JP 2005518379 A JP2005518379 A JP 2005518379A
Authority
JP
Japan
Prior art keywords
mmol
group
different
lower alkyl
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003552769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518379A5 (https=
Inventor
サハグン−クラウゼ，ハイディ
デュ ブレイ，オリヴィエ ティレー
デュ ブレイ，ヴァレリー ティレー
カシラギ，ラウラ
セネチ，ピエルファウスト
クラフキ，ハンス−ヴォルフガング
ブラクスマイヤー，トビアス
ミュラー，シルヴィア
フローネル，ヴォルフガング
モンセ，バルバラ
ゴードン，サンドラ
ローダー，ハンノ
Original Assignee
ナッド アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナッド アーゲー filed Critical ナッド アーゲー
Publication of JP2005518379A publication Critical patent/JP2005518379A/ja
Publication of JP2005518379A5 publication Critical patent/JP2005518379A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2003552769A 2001-12-17 2002-12-04 プロテインキナーゼ阻害剤としてのｎ−炭素環式単置換インドロカルバゾール Pending JP2005518379A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10161940A DE10161940A1 (de) 2001-12-17 2001-12-17 N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
PCT/EP2002/013753 WO2003051887A1 (en) 2001-12-17 2002-12-04 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2005518379A true JP2005518379A (ja) 2005-06-23
JP2005518379A5 JP2005518379A5 (https=) 2006-01-26

Family

ID=7709523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003552769A Pending JP2005518379A (ja) 2001-12-17 2002-12-04 プロテインキナーゼ阻害剤としてのｎ−炭素環式単置換インドロカルバゾール

Country Status (7)

Country Link
US (1) US7262215B2 (https=)
EP (1) EP1456211A1 (https=)
JP (1) JP2005518379A (https=)
AU (1) AU2002356625A1 (https=)
CA (1) CA2467780A1 (https=)
DE (1) DE10161940A1 (https=)
WO (1) WO2003051887A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
CL2007003693A1 (es) 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease
CN102557967A (zh) * 2011-12-28 2012-07-11 合肥科尚医药科技有限公司 一种盐酸氨溴索的制备方法
CN103113379A (zh) * 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
CN117886799B (zh) * 2024-01-11 2025-07-29 浙江工业大学 一类靶向降解GSK-3β的蛋白降解靶向嵌合体化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438050A (en) * 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5547976A (en) * 1992-03-20 1996-08-20 Burroughs Wellcome Co. Further indole derivatives with antiviral activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
GB9416467D0 (en) * 1994-08-13 1994-10-05 Wellcome Found Compounds for use in medicine
DK1044203T3 (da) * 1997-12-31 2003-07-14 Cephalon Inc 3'-epimere K-252a-derivater
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
EP1432721A4 (en) * 2001-09-13 2008-02-20 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF REBECCAMYCIN AND ANALOGUE THEREOF

Also Published As

Publication number Publication date
US20050075386A1 (en) 2005-04-07
DE10161940A1 (de) 2003-07-03
WO2003051887A1 (en) 2003-06-26
US7262215B2 (en) 2007-08-28
EP1456211A1 (en) 2004-09-15
CA2467780A1 (en) 2003-06-26
AU2002356625A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
JP7656087B2 (ja) Ｓｈｐ２活性を阻害する複素環化合物、その製造方法および使用
CA2673368C (en) 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP7462071B2 (ja) Ｃｂｐ／ｅｐ３００阻害剤及びその使用
EP3684762B1 (en) Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
CA2988374A1 (en) Nrf2 regulators
EP2316835A1 (en) Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP2014526453A (ja) ピリジン化合物およびそれらの使用
KR102755639B1 (ko) 바닌 억제제로서의 헤테로방향족 화합물
JP2008520738A5 (https=)
JP2017510653A (ja) ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
AU2016266190A1 (en) Urea derivative or pharmacologically acceptable salt thereof
JP5006046B2 (ja) 新規な縮合ピロロカルバゾール
US5889003A (en) Flavone compounds
EP3704104A1 (en) Irak4 inhibitors and uses thereof
EP4416131A1 (en) Ras inhibitors, compositions and methods of use thereof
FR2876377A1 (fr) Nouveaux derives de 9h-pyrido[2,3-b]indole, leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes
JP2005518379A (ja) プロテインキナーゼ阻害剤としてのｎ−炭素環式単置換インドロカルバゾール
CA3133870A1 (en) Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer
Douara et al. Synthesis and antiproliferative evaluation of glucosylated pyrazole analogs of K252c
EP1565473B1 (en) N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors
Vicentini et al. A new general and efficient synthesis of imidazo [4, 5-c] pyrazole derivatives
Wang et al. Visible-light-induced synthesis of indolo/benzimidazo [2, 1-a] isoquinoline derivatives via decarboxylative glycosylation
WO2025153096A1 (zh) 细胞周期依赖性激酶降解剂及其制备方法和用途
Allentoff et al. Synthesis of an adenine N-3 substituted CBI adduct by alkylation of adenine with a 1-iodomethylindoline seco-CBI precursor
S Ahmed et al. A novel access to arylated and heteroarylated beta-carboline based PDE5 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309